• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Point of Care Diagnostic Testing World Markets - Product Image

Point of Care Diagnostic Testing World Markets

  • ID: 2569956
  • May 2014
  • Region: Global
  • 495 Pages
  • TriMark Publications
Point of Care Diagnostic Testing World Market to Jump to $15.9 Billion by 2018

FEATURED COMPANIES

  • A. Menarini Diagnostics
  • Atlas Genetics Ltd.
  • Chembio Diagnostic, Inc.
  • HemoSense
  • Minimed, Inc.
  • Radiometer Medical
  • MORE

Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.

The report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America.

It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical READ MORE >

Note: Product cover images may vary from those shown
Point of Care Diagnostic Testing World Market to Jump to $15.9 Billion by 2018

FEATURED COMPANIES

  • A. Menarini Diagnostics
  • Atlas Genetics Ltd.
  • Chembio Diagnostic, Inc.
  • HemoSense
  • Minimed, Inc.
  • Radiometer Medical
  • MORE

1. Overview
1.1 About This Report
1.2 Scope of the Report
1.3 Objectives
1.4 Methodology
1.5 Executive Summary

2. Overview of Diagnostic Testing Point of Care Markets
2.1 Key Issues in the POC Diagnostic Testing Sector
2.1.1 Current Market Trends and Drivers
2.1.2 Effectiveness of POCT
2.1.3 New Growth Areas for POCT
2.1.4 Advantages of POCT in a Clinical Setting
2.1.5 Pricing and Reimbursement Issues
2.1.6 Key Customer Segments
2.2 Global Point of Care Marketplace
2.3 Shifts from Central Lab Testing to POCT
2.4 Geographical Distribution
2.5 Challenges of POCT
2.6 Key Issues for POCT
2.6.1 Locations of POCT
2.6.2 Milestones in Technology Development
2.6.3 Drive for Decentralization from Lab to Patient
2.6.4 Competitive Landscape for POCT
2.7 The Future of POCT

3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share
3.1 Global POCT Market

4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share

5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares

6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and
Market Share
6.1 Summary Analysis of the Japanese POCT Market
6.2 Summary Analysis of the Indian POCT Market
6.3 Summary Analysis of the Chinese POCT Market

7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share
7.1 Summary Analysis of the ROW POCT Market Revenues
7.1.1 Summary Analysis of the Argentinian POCT Market
7.1.2 Summary Analysis of the Australian POCT Market
7.1.3 Summary Analysis of the Brazilian POCT Market
7.1.4 Summary Analysis of the Canadian POCT Market
7.1.5 Summary Analysis of the Russian POCT Market
7.1.6 Summary Analysis of the Middle East POCT Market
7.1.7 Summary Analysis of the African POCT Market
7.1.8 Summary Analysis of the Asia (Other) POCT Market
7.1.9 Summary Analysis of the Latin America (Other) POCT Market

8. Review of the Market Segments, Reagents and Equipment
8.1 Blood Glucose Monitoring
8.1.1 Introduction to Blood Glucose Monitoring
8.1.2 Types of Blood Glucose Testing
8.1.2.1 Fasting Blood Sugar (FBS) or Fasting Plasma Glucose (FPG)
8.1.2.2 Two-Hour Postprandial Blood Sugar or Two-Hour PC
8.1.2.3 Random Blood Sugar (RBS)
8.1.2.4 Glucose Urine Test
8.1.2.5 Blood Glucose Test Strip
8.1.2.6 Glycosylated Hemoglobin (HbA1c)
8.1.2.7 Intravenous Glucose Tolerance Test (IVGTT)
8.1.2.8 Oral Glucose Tolerance Test (OGTT)
8.1.3 Segmentation of POC Blood Glucose Testing
8.1.3.1 Continuous Blood Glucose Monitoring (CBGM)
8.1.3.2 Self-Monitoring Blood Glucose (SMBG) Testing
8.1.3.3 Minimally-Invasive and Non-Invasive Blood Glucose Testing
8.1.3.4 Emerging Glucose Monitoring Technologies
8.1.3.5 Optical Transducer Technologies
8.1.3.6 Transdermal Sensor Technologies
8.1.3.7 Invasive Glucose Sensor Technologies
8.1.4 Review of Selected POC Blood Glucose Monitoring Systems
8.1.5 Review of Company Products
8.1.5.1 LifeScan
8.1.5.2 Roche Accu-Chek
8.1.5.3 Abbott Diabetes Care
8.1.5.4 HemoCue
8.1.5.5 Stanbio/GDS Technology
8.1.5.6 Abaxis, Inc.
8.1.5.7 Arkray (Japan)
8.1.5.8 Accurex (India)
8.1.5.9 Home Diagnostics, Inc.
8.1.5.10 Nova Biomedical
8.1.5.11 Bayer Diagnostics
8.1.5.11.1 Hemoglobin A1c Measurements
8.1.5.12 AgaMatrix
8.1.5.13 Akray
8.1.5.14 EKF Diagnostics
8.1.5.15 ACON Laboratories, Inc.
8.1.5.16 Biosite (Now Part of Alere)
8.1.5.17 Siemens Healthcare Diagnostics
8.1.5.18 Infopia
8.1.5.19 Diasys
8.1.5.20 Quotient Dx
8.1.5.21 Cholestech (Acquired by Inverness Medical Innovations, now named Alere)
8.1.5.22 Bio-Rad
8.1.5.23 Axis-Shield
8.1.5.24 Abaxis, Inc.
8.1.6 Market Share for Glucose Testing
8.1.7 Competitive Analysis for the Glucose POCT Sector
8.1.8 Market Analysis
8.1.8.1 Market Drivers
8.1.8.2 Market Restraints
8.1.9 POC Glucose Testing Assay Market and Technology Trends
8.1.9.1 POC Glucose Testing Assay Market Trends
8.1.9.2 POC Glucose Testing Assay Technology Trends
8.1.9.3 POC Glucose Testing Assay Strategic Recommendations
8.2 Blood Gas and Electrolytes
8.2.1 Background to POC Blood Gas and Electrolyte Testing
8.2.1.1 Acid-Base Balance and the Lungs
8.2.1.2 Respiratory Acidosis
8.2.1.3 Respiratory Alkalosis
8.2.1.4 Metabolic (or Non-Respiratory) Acidosis
8.2.1.5 Metabolic (or Non-Respiratory) Alkalosis
8.2.1.6 Increasing Popularity of POC Blood Gas and Electrolyte Testing
8.2.2 Market Segmentation (Segmentation by Type of Blood Gas Monitoring Equipment)
8.2.2.1 Intermittent Blood Gas Monitoring Equipment
8.2.2.2 Continuous Blood Gas Monitoring Equipment
8.2.2.3 EABG Monitors
8.2.2.4 IABG Monitors
8.2.2.5 Portable Blood Gas Analyzers
8.2.2.6 Patient-Attached On-Demand Blood Gas Analyzers
8.2.3 Applications for POCT Blood Gas and Electrolyte Analyzers
8.2.4 Emerging Technologies
8.2.5 Whole-Blood Lactate
8.2.6 Creatinine
8.2.7 Electrolytes Point of Care Analysis: Comparison of POCT and Central Lab Results
8.2.8 Review of Selected Blood Gas and Electrolyte Analyzers
8.2.9 Review of Company Products
8.2.9.1 Roche Corporation
8.2.9.2 TechnoMedica
8.2.9.3 Siemens Healthcare Diagnostics
8.2.9.4 Instrumentation Laboratory
8.2.9.5 Nova Biomedical
8.2.9.6 Radiometer
8.2.9.7 Abbott Point of Care
8.2.9.8 Span Diagnostics
8.2.9.9 ITC AVOXimeter Systems for CO-oximetry
8.2.9.10 ITC (Nexus Dx)
8.2.9.11 Alere
8.2.9.12 Abaxis, Inc.
8.2.9.13 Opti Medical
8.2.9.14 Arkray USA
8.2.10 Market Share for Blood Gas and Electrolyte Testing
8.2.11 Competitive Analysis for the Blood Gas and Electrolyte Point of Care Testing Sector
8.2.12 Market Analysis
8.2.12.1 Market Drivers
8.2.12.2 Market Restraints
8.2.13 POC Blood Gas and Electrolyte Testing Assay Market and Technology Trends
8.2.13.1 POC Blood Gas and Electrolyte Testing Assay Market Trends
8.2.13.2 POC Blood Gas and Electrolyte Testing Assay Technology Trends
8.2.13.3 POC Blood Gas and Electrolyte Testing Assay Strategic Recommendations
8.3 Rapid Coagulation Tests
8.3.1 Background to Rapid Coagulation Tests
8.3.2 Review of Selected POC Rapid Coagulation Analyzers
8.3.3 Review of Company Products
8.3.3.1 Roche Diagnostics Corp.
8.3.3.2 Abbott Laboratories
8.3.3.3 International Technidyne Corporation Nexus DX
8.3.3.4 Medtronic
8.3.3.5 Alere
8.3.3.6 Helena Laboratories Point of Care
8.3.3.7 Sienco, Inc.
8.3.3.8 Accumetrics (ITC Nexus Holding Company)
8.3.3.9 Alere
8.3.3.10 ITC
8.3.3.11 Instrumentation Laboratory's GEM PCL Plus
8.3.3.12 Others
8.3.3.13 Self-Monitoring Products
8.3.3.14 Platelet Function and Antiplatelet Drug Assessment
8.3.4 Connectivity Issues
8.3.5 Cost Benefits
8.3.6 Quality Control Issues
8.3.7 Certification for POC Coagulation Devices
8.3.8 D-Dimer Testing
8.3.9 Market Analysis
8.3.9.1 Market Share for POCT Coagulation Testing
8.3.9.2 Competitive Analysis of Sector Companies
8.3.9.3 Market Drivers
8.3.9.4 Market Restraints
8.3.9.5 POC Coagulation Testing Assay Market Trends
8.3.9.6 POC Coagulation Testing Assay Technology Trends
8.3.9.7 POC Coagulation Testing Assay Strategic Recommendations
8.3.9.8 SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Coagulation POC Market
8.4 POC Rapid Cardiac Markers
8.4.1 Background to POC Rapid Cardiac Marker Testing
8.4.2 Cardiac Marker Tests
8.4.2.1 Creatine Kinase (CK)
8.4.2.2 Myoglobin
8.4.2.3 Cardiac Troponins T (TnT), I (TnI) and C (TnC)
8.4.2.4 C-Reactive Protein (CRP)
8.4.2.5 Homocysteine
8.4.3 Emerging Markers
8.4.3.1 B-Type Natriuretic Peptide (BNP)
8.4.3.2 Myeloperoxidase (MPO)
8.4.3.3 Ischemia-Modified Albumin (IMA)
8.4.3.4 Glycogen Phosphorylase Isoenzyme BB (GPBB)
8.4.3.5 Fatty Acid-Binding Proteins (FABPs)
8.4.4 Review of Selected POC Cardiac Biomarker Analyzers
8.4.5 Review of Company Products
8.4.5.1 Alere Triage Cardiac Panel
8.4.5.2 Roche Diagnostics
8.4.5.3 Any Biotech
8.4.5.4 Response Biomedical Corporation
8.4.5.5 Siemens Healthcare Diagnostics (f/k/a Bayer Healthcare Diagnostics, Diagnostic Products Corporation and Dade Behring)
8.4.5.6 Abbott Point of Care
8.4.5.7 LifeSign (Princeton BioMediTech Corp.)
8.4.5.8 Mitsubishi Kagaku Iatron
8.4.5.9 Alpha Scientific
8.4.5.10 bioMérieux
8.4.5.11 Nexus
8.4.5.12 Princeton BioMeditech
8.4.5.13 Randox Laboratories
8.4.5.14 Market Share for Cardiac Marker Testing
8.4.6 Market Analysis
8.4.6.1 Market Drivers
8.4.6.2 Market Restraints
8.4.7 POC Cardiac Marker Testing Assay Market and Technology Trends
8.4.7.1 POC Cardiac Marker Testing Assay Market Trends
8.4.7.2 POC Cardiac Marker Testing Assay Technology Trends
8.4.7.3 POC Cardiac Marker Testing Assay Strategic Recommendations
8.5 POC Substance Abuse Testing
8.5.1 Background to POC Substance Abuse Testing
8.5.2 Substance Abuse Test Types
8.5.2.1 Urine Substance/Drug Screening
8.5.2.2 Hair Tests for Substance Abuse and Screening
8.5.2.3 Blood Tests for Substance Abuse and Screening
8.5.2.4 Saliva Tests for Substance Abuse and Screening
8.5.2.5 Sweat Tests for Substance Abuse and Screening
8.5.3 Alcohol Abuse and Screening
8.5.4 Saliva Testing
8.5.5 Qualitative Analysis
8.5.5.1 Market Drivers
8.5.5.2 Market Restraints
8.5.6 Review of Selected POC Substance Abuse Analyzers
8.5.7 Review of Company Products
8.5.7.1 Alere
8.5.7.2 Abbott Diagnostics
8.5.7.3 BTNX, Inc.
8.5.7.4 BioScan Screening Systems, Inc.
8.5.7.5 American Bio Medica Corp.
8.5.7.6 Phamatech, Inc.
8.5.7.7 First Check Diagnostics Corp. (Alere, Inc.)
8.5.7.8 OraSure
8.5.7.9 Noble Medical, Inc.
8.5.7.10 Guangzhou Wondfo Biotech Co., Ltd.
8.5.7.11 Pathtech
8.5.7.12 Alfa Scientific Designs, Inc.
8.5.7.13 TCPI, Inc.
8.5.7.14 Biophor Diagnostics
8.5.7.15 Randox Laboratories
8.5.7.16 Branan Medical
8.5.7.17 Concateno
8.5.7.18 LifeSign
8.6 POC Pregnancy and Fertility Tests
8.6.1 Background to POC Pregnancy and Fertility Tests
8.6.2 Review of Selected POC Pregnancy Testing Devices
8.6.3 Review of Company Products
8.6.3.1 Quidel
8.6.3.2 Abbott Diagnostics
8.6.3.3 Alere
8.6.3.4 Worldwide Medical Corporation
8.6.3.5 Sekisui Diagnostics, LLC
8.6.3.6 Siemens Diagnostics
8.6.3.7 Orgenics (A subsidiary of Alere)
8.6.3.8 LifeSign
8.6.3.9 Stanbio
8.6.3.10 Market Analysis
8.6.3.10.1 Competitive Sector Analysis
8.7 Fecal Occult Blood
8.7.1 Background to POC Fecal Occult Blood Testing
8.7.2 Review of Selected POC Fecal Occult Testing Devices
8.7.3 Review of Company Products
8.7.3.1 Helena Laboratories
8.7.3.2 Biomerica
8.7.3.3 Beckman Coulter
8.7.3.4 Worldwide Medical
8.7.3.5 Aerscher Diagnostics
8.7.3.6 Enterix
8.7.3.7 Medix Biochemica
8.7.3.8 Orion Diagnostica
8.7.3.9 ACON Laboratories' Mission FOB Reagent Strips
8.7.3.10 Alere's Products
8.7.3.11 Immunostics' Hema-Screen
8.7.3.12 Princeton BioMeditech's BioSign iFOBTest
8.7.3.13 Quest Diagnostics' InSure FIT
8.7.3.14 Quidel's QuickVue iFOB
8.7.4 Market Share for Fecal Occult Blood Testing
8.7.4.1 Company Analysis for the Fecal Occult Blood POCT Sector
8.7.5 Market Analysis
8.7.5.1 Market Drivers
8.7.5.2 Market Restraints
8.7.5.3 POC Fecal Occult Blood Testing Assay Market and Technology Trends
8.7.5.3.1 POC Fecal Occult Blood Testing Assay Market Trends
8.7.5.3.2 Fecal Occult Blood Testing Assay Technology Trends
8.7.5.3.3 POC Fecal Occult Blood Testing Assay Strategic Recommendations
8.8 POC Infectious Disease Testing
8.8.1 Background to POC Infectious Disease Testing
8.8.2 Types of Diagnosis for Infectious Diseases
8.8.2.1 Microbial Culture
8.8.2.2 Microscopy
8.8.2.3 Biochemical Tests
8.8.2.4 Molecular Diagnostics
8.8.3 Diagnostic Platforms for Infectious Diseases
8.8.3.1 Centralized Laboratory Testing for Infectious Diseases
8.8.3.2 POC Testing for Infectious Diseases
8.8.4 Emerging Technologies
8.8.5 Qualitative Analysis
8.8.5.1 Market Drivers
8.8.5.2 Market Restraints
8.8.6 Review of Selected POC Infectious Disease Testing Devices
8.9 POC Urine Strip Testing
8.9.1 Background to POC Urine Strip Testing
8.9.2 Emerging Technologies
8.9.3 Review of Selected POC Urine Strip Testing Devices
8.10 POC Cholesterol Testing
8.10.1 POC Cholesterol Testing Market Size and Development
8.10.2 Background to POC Cholesterol Testing
8.10.3 POC Cholesterol Testing Devices
8.10.3.1 Review of Selected POC Cholesterol Testing Devices
8.10.4 Review of Company Products
8.10.4.1 Cholestech (Now Alere)
8.10.4.2 Actimed Laboratories
8.10.4.3 StatSite Meter
8.10.4.4 Polymer Technology Systems
8.10.4.5 Miraculins
8.10.4.6 Abaxis, Inc.
8.10.5 Product Comparison of Leading Suppliers
8.10.6 Launch Dates of Leading Products in Europe
8.11 Miscellaneous POC Tests
8.11.1 Triage C. difficile Panel
8.11.2 Ketoacids
8.11.3 Acetaminophen
8.11.4 Estriol
8.11.5 POC H. pylori Testing
8.11.6 Bacterial Contamination of Platelet Units
8.12 POC Vaginal Fluid pH and Vaginitis Testing
8.13 POC Cancer Testing
8.13.1 Prostate-Specific Antigen (PSA)
8.13.2 Bladder Cancer
8.13.3 Other Rapid Cancer Tests
8.14 Fetal Status (PROM)
8.15 Osteoporosis
8.16 Hemodynamic Monitoring
8.17 Heparin-Induced Thrombocytopenia
8.18 HIV
8.18.1 Whole-Blood, Serum or Plasma-Based HIV Tests
8.18.1.1 Bio-Rad Laboratories
8.18.1.2 Orgenics (Inverness, Now Alere)
8.18.1.3 StatSure Diagnostic Systems
8.18.1.4 Trinity Biotech
8.18.1.5 Savyon Diagnostics
8.18.1.6 MedPharm
8.18.1.7 American Bio Medica Corp.
8.18.1.8 Chembio Diagnostics
8.18.1.9 OraSure Technologies
8.18.1.10 Alere
8.18.1.11 Hema Diagnostics Systems
8.18.1.12 bioLytical Laboratories' INSTI Kit
8.18.1.13 bioMérieux's VIKIA HIV-1/2 Test
8.18.1.14 Chembio Diagnostics' Dual-Path Platform Technology Products
8.18.1.15 Daktari Diagnostics' Daktari CD4
8.18.1.16 EY Laboratories' InstantCHEK
8.18.1.17 IND Diagnostic's One-Step Anti-HIV (1+2) Test
8.18.1.18 IQuum's Liat System
8.18.1.19 Lab21's Biotec Tests
8.18.1.20 MedMira's HIV Tests
8.18.1.21 YD Diagnostics' AIDScan
8.18.2 Saliva-Based HIV Tests
8.18.2.1 OraSure Collection Device
8.18.2.2 SureStat
8.18.2.3 Calypte
8.18.3 Urine-Based HIV Tests
8.18.3.1 MedMira Laboratories, Inc.
8.18.3.2 Medical Services International, Inc.
8.18.3.3 Maxim Biomedical
8.18.3.4 Wampole Laboratories
8.19 Infectious Diseases
8.19.1 C. difficile
8.19.2 Giardia
8.19.3 Dengue Fever
8.19.4 Malaria Testing
8.19.5 Rapid Influenza Testing
8.19.6 Streptococcus Testing
8.19.7 Chlamydia
8.19.8 Mononucleosis
8.19.9 Rubella
8.19.10 Staphylococcus aureus and MRSA
8.19.11 Hepatitis
8.19.12 E. coli O157
8.19.13 Gonorrhea Testing
8.19.14 Smallpox
8.19.15 SARS
8.19.16 Rabies
8.19.17 Tuberculosis
8.19.18 Avian Flu
8.19.19 West Nile Virus
8.19.20 Herpes Simplex Virus Type-2
8.19.21 Legionella
8.19.22 RSV
8.19.23 Leptospirosis
8.19.24 Sexually-Transmitted Diseases
8.19.25 Infant Jaundice
8.19.26 Anthrax
8.19.27 Tropical Diseases
8.20 Homeland Defense (Plague and Tularemia)
8.21 BSE (Mad Cow Disease)
8.22 Tuberculosis
8.23 Typhoid
8.24 Avian Flu
8.25 Food Pathogens (Salmonella, Listeria, Campylobacter)
8.26 Ruptured Fetal Membranes
8.27 Alcohol
8.28 Microalbumin Testing
8.29 Labor and Delivery Testing
8.29.1 Alere Triage PLGF
8.29.2 Amnisure
8.29.3 Medix Biochemica
8.30 Sperm Fertility
8.31 Surgical Coagulation and Hemostasis Management
8.32 Respiratory Tests
8.33 C-Reactive Protein

9. POCT: Growth Regulators
9.1 Moderators of Growth
9.2 Personnel Acceptance
9.3 Key People for POCT
9.4 Information Management Issues
9.4.1 Elements of Information Management for POCT: Information-Processing Capabilities
9.4.2 Data Mining
9.4.3 Middleware
9.4.4 Web Portals
9.4.5 POCT-1A Standard
9.5 Key Elements for POCT
9.6 POCT and Reimbursement
9.7 Effectiveness of Clinical Outcomes
9.8 Rapid Near-Patient Testing in Hospitals
9.9 Satellite Facilities
9.10 Regionalization of Laboratory Care
9.11 Requirements for POCT
9.12 Locations of POC for Patient Care
9.13 Benefits of POCT
9.14 Cost Elements of POCT
9.15 Necessary Functions in POCT
9.16 Turnaround Time (TAT) for POCT
9.17 Clinical Laboratory Improvement Amendments (CLIA)
9.18 Sexually-Transmitted Diseases in Underdeveloped Countries
9.19 Sources of Error in POC Testing

10. Business Trends in the POC Sector
10.1 Sector Consolidation
10.2 Diagnostic Testing Growth Trends
10.2.1 Opportunities for Healthcare Stakeholders
10.3 Acquisition, License Agreements, Internal Development and Partnerships
10.4 Product Testing Depth in POCT
10.5 Government Regulation
10.5.1 U.S. Regulation
10.5.1.1 Importing Medical Devices into the U.S.
10.5.1.2 Exporting Medical Devices from the U.S.
10.5.2 E.U. Regulation
10.5.3 Japanese Regulation
10.5.4 Korean Regulation
10.6 Post-Filing Regulations for POC Devices
10.7 Exporting Unapproved POCTs
10.8 Analyte-Specific Reagents (“Home-Brew” Tests)
10.9 Medical Device Registration
10.10 Product Labeling
10.11 Punitive FDA Actions
10.12 CLIA ‘88 and State Laboratory Laws
10.13 Impact of Regulations on the Industry
10.14 Minimizing Regulatory Barriers
10.15 Waived Testing

11. Technology Platform Innovations in POCT
11.1 Latest POCT Technological Platforms
11.1.1 Device Miniaturization and Microfluidic Technologies
11.1.2 Minimally-Invasive and Non-Invasive POCT Technologies
11.1.2.1 Via Medical
11.1.2.2 Echo Therapeutics
11.1.3 Advances in Wireless Technologies
11.1.4 Automation of POCT
11.1.5 Developments in New Genomic Technologies (Genotyping, Haplotyping and Sequencing Technologies)
11.1.6 Advances in Informatics Technologies
11.1.7 Pharmacogenetic Testing
11.1.8 Multi-Assay Technologies in POCT
11.2 Developments in Key Technologies
11.2.1 Medical and Biological Sensors and Sensor Systems
11.2.2 Recent Biosensor Product Introductions and the Latest Innovative Developments
11.2.2.1 Nanoscale Sensors for the Detection of Cancer Biomarkers
11.2.2.2 ForteBio Introduces Dip and Read Protein G Biosensor for Octet Instruments
11.2.2.3 ForteBio Launches New Octet RED96 System and Dip and Read Protein L Biosensor
11.2.2.4 AgaMatrix Europe Limited Introduces New Jazz Blood Glucose Meter in the U.K.
11.2.2.5 STMicroelectronics to Manufacture the World's Smallest Biosensors
11.2.2.6 Universal Biosensors Advances POC Molecular Diagnostic Opportunity
11.2.2.7 Clinitek Advantus—A Semi-Automated Urine Analyzer for POC Testing
11.2.2.8 NOVA 16 STAT Chemistry Analyzer Offers the First All-Electrode-Based Seven-Test Chemistry Profile
11.3 Sensor Systems for Diagnostic Applications
11.4 Nanogen (The ELITech Group) Third-Generation POC Analyzer
11.5 Philips Development of Magnotech Technology
11.6 Quidel Corporation MChip, AVR Chip and F Chip
11.7 Sanofi-Aventis
11.8 Siloam Biosciences Trova Open Source Point of Care System
11.9 Smart Phone Technology
11.9.1 Aquila Diagnostic Systems, Inc.
11.9.2 AgaMatrix
11.10 Sirigen HSF Technology

12. Data Management and Connectivity
12.1 Wireless LANs
12.2 Connectivity Platforms
12.2.1 DataLink Data Management System
12.2.2 RALS-Plus, RALS-Web3 and RALS-Freedom
12.2.2.1 International Technidyne Corporation HEMOCHRON Signature Elite
12.2.2.2 Siemens Diagnostics Rapidpoint Coag
12.2.2.3 Radiometer
12.2.2.4 HemoCue's DM Hemoglobin
12.2.2.5 Roche Diagnostics
12.2.2.6 ITC
12.2.3 BD.id
12.2.4 Medical Implant Communications Service (MICS)
12.2.5 Conworx Technology
12.2.6 Lab Data Systems
12.2.7 Medasys
12.2.8 NoemaLife
12.2.9 Telcare
12.3 Advantages of POCT Connectivity
12.3.1 Cost-Benefit Analysis of POCT and IT Connectivity
12.3.2 Hospital Network Issues
12.4 POCT Analyzer Connectivity Software Solutions
12.5 POCT2-P

13. Corporate Profiles
13.1 Abaxis, Inc.
13.2 Abbott Laboratories
13.3 AccuBioTech Co., Ltd.
13.4 Accumetrics, Inc. (Accriva Diagnostics)
13.5 AccuTech, LLC
13.6 ACON Laboratories, Inc.
13.7 Acrongenomics
13.8 AgaMatrix
13.9 Aerscher Diagnostics, LLC
13.10 Akers Biosciences, Inc.
13.11 Alere
13.12 Alfa Scientific Designs, Inc.
13.13 American Bio Medica Corporation
13.14 Any Biotech Oyo Ltd.
13.15 Ark Therapeutics Group Plc
13.16 Arkray, Inc.
13.17 Atlas Genetics Ltd.
13.18 Atonomics A/S
13.19 Audit Diagnostics
13.20 Augurix Diagnostics Ltd.
13.21 Axis-Shield Plc (Alere)
13.22 Axxin
13.23 Bayer Corp.
13.24 Beckman Coulter (Danaher Corporation)
13.25 BioLytical Laboratories
13.26 Biomerica, Inc.
13.27 bioMérieux
13.28 BiOracle
13.29 Bio-Rad Laboratories, Inc.
13.30 BioScan Screening Systems, Inc.
13.31 BioSite
13.32 Calmark Sweden AB
13.33 Calypte Biomedical Corporation
13.34 Chembio Diagnostic, Inc.
13.35 Chempaq A/S
13.36 Cholestech
13.37 Claros Diagnostics (OPKO Healthcare)
13.38 CompuCyte Corporation (Thorlabs)
13.39 Concateno Plc
13.40 Dexcom
13.41 Diagnostics for All
13.42 Enigma Diagnostics Ltd.
13.43 EY Laboratoires, Inc.
13.44 Eurotrol
13.45 Exalenz Bioscience
13.46 GenBio
13.47 Genzyme Diagnostics (Acquired by Sekisui Chemical Co., Ltd)
13.48 Guided Therapeutics, Inc. (SpectRx, Inc.)
13.49 Helena Laboratories
13.50 Hema Diagnostic Systems, LLC
13.51 HemoCue AB
13.52 HemoSense
13.53 Home Diagnostics (Nipro Diagnostics)
13.54 IND Diagnostic
13.55 Instrumentation Laboratory (IL)/Werfen Group
13.56 International Technidyne Corporation (ITC)
13.57 Jant Pharmacal Corporation
13.58 Johnson & Johnson
13.59 Lein Applied Diagnostics
13.60 LifeAssays AB
13.61 LifeSign, LLC
13.62 Medica Corporation
13.63 Medical Automation Systems
13.64 Mediwatch
13.65 Medix Biochemica
13.66 MedMira Laboratories
13.67 MELA Sciences (Formerly Electro-Optical Sciences)
13.68 A. Menarini Diagnostics
13.69 Meretek Diagnostics Group
13.70 Meridian Bioscience
13.71 Micronics
13.72 Minimed, Inc.
13.73 Mitsubishi Chemical Holdings USA, Inc.
13.74 Mitsubishi Kagaku Iatron
13.75 Nanogen (ELITech Group)
13.76 New Horizons Diagnostics
13.77 Nexus/ITC
13.78 Nova Biomedical
13.79 OraSure Technologies, Inc.
13.80 Orion Diagnostica
13.81 Polymedco, Inc.
13.82 Polymer Technology Systems, Inc.
13.83 Prima Biomedical Company
13.84 QBC Diagnostics
13.85 Qualigen
13.86 Quest Diagnostics, Inc.
13.87 Quidel Corporation
13.88 Radiometer Medical
13.89 Response Biomedical Corp.
13.90 Roche Diagnostics
13.91 Savyon Diagnostics
13.92 Seegene
13.93 Sekisui Diagnostics, LLC
13.94 Selfcare, Inc.
13.95 Shanghai Ruicare Medical Co., Ltd.
13.96 Shenzhen Fitconn Technology Co., Ltd.
13.97 Shionogi & Co., Ltd.
13.98 Siemens AG
13.99 Siloam Biosciences, Inc.
13.100 Spectral Diagnostics, Inc.
13.101 StatSure Diagnostic Systems, Inc.
13.102 Step Detect Associates, LLC
13.103 Strategic Diagnostics, Inc.
13.104 Techne Corporation
13.105 Telcare
13.106 Trinity Biotech Plc
13.107 Väsamed, Inc.

14. POCT Sector Trends and Forecasts
14.1 Home Care Analysis as Part of Near-Patient Testing
14.2 Non-Traditional Collection for POCT
14.3 New Systems for Critical Care and Near-Patient Testing
14.4 Utility of Near-Patient Testing in Critical-Care Settings
14.5 Physician's Office Market
14.6 Information Management Advances
14.7 Test-Ordering Patterns and Demand for POCT
14.8 Demand for Emergency Department Services
14.9 Move Away from the Central Laboratory
14.10 Healthcare Cost Controls
14.11 Mergers and Acquisitions in POCT
14.12 Competition for Services
14.13 Drivers of POCT
14.14 Confluence of New Technology
14.15 Difficulties of Design for POC Products
14.16 European Hospital Structure
14.17 The Biggest New Opportunities in POCT

15. New Entrants to the Point of Care Market
15.1 Alliance International Co., Ltd.
15.2 Alverix, Inc.
15.3 Analyticon Biotechnologies AG
15.4 Aptiva Medical Corporation
15.5 Aquila Diagnostic Systems, Inc.
15.6 ArcDia International Oyo Ltd.
15.7 Artron Laboratories, Inc.
15.8 Atlas Genetics Ltd.
15.9 Atlas Link Biotech Co., Ltd.
15.10 Atonomics A/S
15.11 Audit Diagnostics
15.12 Augurix SA/Augurix Diagnostics
15.13 Autobio Diagnostics Co., Ltd.
15.14 Axxin
15.15 Biocartis SA
15.16 BioFire Diagnostics, Inc.
15.17 BioHelix Corporation
15.18 BioMedomics
15.19 Biosensia Ltd.
15.20 Curetis AG
15.21 DxNA, LLC
15.22 Echo Therapeutics, Inc.
15.23 Enigma Diagnostics Ltd.
15.24 Gentag, Inc.
15.25 Great Basin Corporation
15.26 Immunexpress Group
15.27 Innovative Biosensors, Inc.
15.28 Integrated Diagnostics
15.29 Integrity Applications
15.30 MBio Diagnostics, Inc.
15.31 Menssana Research, Inc.
15.32 Metaara Medical Technologies, Inc.
15.33 QuantuMDx Group
15.34 Venaxis, Inc.
15.35 Vivacta Limited
15.36 Wave 80 Biosciences
15.37 Veredus Laboratories Pte Ltd.
15.38 Via Medical Corporation
15.39 Vital Diagnostics, Inc.

INDEX OF FIGURES

Figure 2.1: Worldwide Distribution of IVD Testing, 2013
Figure 2.2: Top 13 Country IVD Testing Markets, 2013
Figure 2.3: Market Share for IVD Testing by Company, 2013
Figure 3.1: Total Global POCT Market, 2008-2018
Figure 3.2: Worldwide Distribution of POCT, 2013
Figure 3.3: Summary of Global POCT Markets by Market Segment, 2013
Figure 4.1: U.S. Revenues for POCT Market, 2008-2018
Figure 4.2: Summary of U.S. POCT Markets by Market Segment, 2013
Figure 5.1: European Revenues for POCT Market, 2008-2018
Figure 6.1: Summary Analysis of Japanese, Chinese and Indian POCT Market, 2008-2018
Figure 6.2: Japanese Revenues for POCT Market, 2008-2018
Figure 6.3: Indian Revenues for POCT Market, 2008-2018
Figure 6.4: Chinese Revenues for POCT Market, 2008-2018
Figure 7.1: Summary Analysis of ROW POCT Market, 2008-2018
Figure 7.2: Summary Analysis of Russian Revenues for POCT Products Market, 2008-2018
Figure 7.3: Summary Analysis of Middle East Revenues for POCT Products Market, 2008-2018
Figure 7.4: Summary Analysis of African Revenues for POCT Products Market, 2008-2018
Figure 7.5: Summary Analysis of Latin America (Other) Revenues for POCT Products Market, 2008-2018
Figure 8.1: Global Share of Glucose Testing Market by Company, 2013
Figure 8.2: Global POCT Share of Blood Gas and Electrolyte Testing Market, 2013
Figure 8.3: Global POCT Share of Coagulation Testing Market, 2013
Figure 8.4: Global POCT Share of Cardiac Marker Testing Market, 2013
Figure 8.5: Global POCT Share of HIV Testing Market, 2013
Figure 8.6: Performance Metrics of ROM Diagnostic Methods
Figure 9.1: Annual Rate of Emergency Room Visits by Primary Expected Source of Payment
Figure 9.2: CLIA Laboratories by Certificate Types
Figure 10.1: Conformity Assessment Route, Annexes and Quality System Standards by IVD Device
Category
Figure 12.1: The RALS Data Management System Connects to Most of the Major Instruments Used in
Point of Care
Figure 12.2: AegisPOC Point of Care and Critical Care Connectivity and Information Management System

INDEX OF TABLES

Table 2.1: Summary of Global POCT Markets by Major Market Sub-Segment, 2013 and 2018
Table 2.2: Summary of U.S. POCT Markets by Major Market Sub-Segment, 2013 and 2018
Table 2.3: Summary of European POCT Markets by Major Market Sub-Segment, 2013 and 2018
Table 2.4: Summary of Asian POCT Markets by Major Market Sub-Segment, 2013 and 2018
Table 2.5: Summary of ROW POCT Markets by Major Market Sub-Segment, 2013 and 2018
Table 2.6: Worldwide POCT Market Size by Geographic Location, 2008-2018
Table 2.7: Global Market Share POCT Analysis, 2013
Table 2.8: Worldwide Distribution of IVD Testing, 2013
Table 2.9: Top 13 Country IVD Testing Markets, 2013
Table 2.10: Company Market Share for IVD Testing Markets, 2013
Table 2.11: Competitive Landscape for POC Diagnostic Testing
Table 3.1: Total Global POCT Market, 2008-2018
Table 3.2: Global Revenues for POC Blood Glucose Monitoring Systems, 2008-2018
Table 3.3: Global Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018
Table 3.4: Global Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018
Table 3.5: Global Revenues for POC Cardiac Marker Devices, 2008-2018
Table 3.6: Global Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2018
Table 3.7: Global Revenues for POC Infectious Disease Testing Devices Market, 2008-2018
Table 3.8: Global Revenues for POC Urine Strip Testing Products Market, 2008-2018
Table 3.9: Global Revenues for POC Pregnancy Testing Devices Market, 2008-2018
Table 3.10: Global Revenues for POC Fecal Occult Testing Devices Market, 2008-2018
Table 3.11: Global Revenues for POC Cholesterol Testing Products Market, 2008-2018
Table 3.12: Global POCT Market Share Analysis, 2013
Table 3.13: Worldwide POCT Market Size by Geographic Location, 2008-2018
Table 3.14: Worldwide Distribution of POCT, 2013
Table 3.15: Summary of Global POCT Markets by Market Segment, 2013
Table 3.16: Worldwide POCT by Performance Location, 2013
Table 4.1: U.S. Revenues for POCT Market, 2008-2018
Table 4.2: U.S Revenues for POC Blood Glucose Monitoring Systems, 2008-2018
Table 4.3: U.S Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018
Table 4.4: U.S. Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018
Table 4.5: U.S. Revenues for POC Cardiac Marker Devices, 2008-2018
Table 4.6: Market Share of U.S. POCT Cardiac Marker Market, 2013
Table 4.7: U.S. Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2018
Table 4.8: U.S. Revenues for POC Infectious Disease Testing Devices Market, 2008-2018
Table 4.9: U.S. Revenues for POC Urine Strip Testing Products Market, 2008-2018
Table 4.10: U.S. Revenues for POC Pregnancy Testing Devices Market, 2008-2018
Table 4.11: U.S. Revenues for POC Fecal Occult Testing Devices Market, 2008-2018
Table 4.12: U.S. Revenues for POC Cholesterol Testing Products Market, 2008-2018
Table 4.13: U.S. POCT Market Share Analysis, 2013
Table 4.14: U.S. POCT by Performance Location, 2013
Table 4.15: Summary of U.S. POCT Markets by Market Segment, 2013
Table 5.1: Models of Public-Private Partnership in Hospital Provision
Table 5.2: European Revenues for POCT Market, 2008-2018
Table 5.3: French Revenues for POCT Systems, 2008-2018
Table 5.4: German Revenues for POCT Systems, 2008-2018
Table 5.5: Italian Revenues for POCT Systems, 2008-2018
Table 5.6: Spanish Revenues for POCT Systems, 2008-2018
Table 5.7: U.K. Revenues for POCT Systems, 2008-2018
Table 5.8: Benelux Revenues for POCT Systems, 2008-2018
Table 5.9: Scandinavian Revenues for POCT Systems, 2008-2018
Table 5.10: Rest-of-Europe Revenues for POCT Systems, 2008-2018
Table 5.11: European Revenues for POC Blood Glucose Monitoring Systems, 2008-2018
Table 5.12: European Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018
Table 5.13: European Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018
Table 5.14: European Revenues for POC Cardiac Marker Devices, 2008-2018
Table 5.15: European Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2018
Table 5.16: European Revenues for POC Infectious Disease Testing Devices Market, 2008-2018
Table 5.17: European Revenues for POC Urine Strip Testing Products Market, 2008-2018
Table 5.18: European Revenues for POC Pregnancy Testing Devices Market, 2008-2018
Table 5.19: European Revenues for POC Fecal Occult Testing Devices Market, 2008-2018
Table 5.20: European Revenues for POC Cholesterol Testing Products Market, 2008-2018
Table 5.21: European Market Share Analysis, 2013
Table 6.1: Summary Analysis of Japanese, Chinese and Indian POCT Market, 2008-2018
Table 6.2: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Blood Glucose Monitoring Systems, 2008-2018
Table 6.3: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018
Table 6.4: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018
Table 6.5: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Cardiac Marker Devices,
2008-2018
Table 6.6: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2018
Table 6.7: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Infectious Disease Testing Devices Market, 2008-2018
Table 6.8: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Urine Strip Testing Products Market, 2008-2018
Table 6.9: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Pregnancy Testing Devices Market, 2008-2018
Table 6.10: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Fecal Occult Testing Devices Market, 2008-2018
Table 6.11: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Cholesterol Testing Products Market, 2008-2018
Table 6.12: Summary Analysis of Japanese, Chinese and Indian Market Shares, 2013
Table 6.13: Japanese Population and Aging Demographics Forecast, 2000-2050
Table 6.14: Japanese Revenues for POCT Market, 2008-2018
Table 6.15: Indian Revenues for POCT Market, 2008-2018
Table 6.16: Chinese Revenues for POCT Market, 2008-2018
Table 7.1: Summary Analysis of ROW POCT Market, 2008-2018
Table 7.2: Summary Analysis of ROW Revenues for POC Blood Glucose Monitoring Systems,
2008-2018
Table 7.3: Summary Analysis of ROW Revenues for POC Blood Gas and Electrolyte Analyzers,
2008-2018
Table 7.4: Summary Analysis of ROW Revenues for POC Rapid Coagulation Analyzer Systems,
2008-2018
Table 7.5: Summary Analysis of ROW Revenues for POC Cardiac Marker Devices, 2008-2018
Table 7.6: Summary Analysis of ROW Revenues for POC Substance/Drug Abuse Testing Device Market,
2008-2018
Table 7.7: Summary Analysis of ROW Revenues for POC Infectious Disease Testing Devices Market,
2008-2018
Table 7.8: Summary Analysis of ROW Revenues for POC Urine Strip Testing Products Market,
2008-2018
Table 7.9: Summary Analysis of ROW Revenues for POC Pregnancy Testing Devices Market,
2008-2018
Table 7.10: Summary Analysis of ROW Revenues for POC Fecal Occult Testing Devices Market,
2008-2018
Table 7.11: Summary Analysis of ROW Revenues for POC Cholesterol Testing Products Market,
2008-2018
Table 7.12: Summary Analysis of ROW Market Shares, 2013
Table 7.13: Summary Analysis of Argentinian Revenues for POCT Products Market, 2008-2018
Table 7.14: Summary Analysis of Australian Revenues for POCT Products Market, 2008-2018
Table 7.15: Summary Analysis of Brazilian Revenues for POCT Products Market, 2008-2018
Table 7.16: Summary Analysis of Canadian Revenues for POCT Products Market, 2008-2018
Table 7.17: Summary Analysis of Russian Revenues for POCT Products Market, 2008-2018
Table 7.18: Summary Analysis of Middle East Revenues for POCT Products Market, 2008-2018
Table 7.19: Summary Analysis of African Revenues for POCT Products Market, 2008-2018
Table 7.20: Summary Analysis of Asia (Other) Revenues for POCT Products Market, 2008-2018
Table 7.21: Summary Analysis of Latin America (Other) Revenues for POCT Products Market,
2008-2018
Table 8.1: Summary of Emerging Glucose Sensor Technologies, 2013
Table 8.2: Selected POC Blood Glucose Monitoring Systems, 2013
Table 8.3: Roche Diagnostics Glucose Testing Products
Table 8.4: Global Share of Glucose Testing Market by Company, 2013
Table 8.5: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Glucose
POC Market
Table 8.6: Distribution of Blood Gas Testing in Hospitals, 1990 and 2012
Table 8.7: Selected POC Blood Gas and Electrolyte Analyzers, 2013
Table 8.8: Market Share of Blood Gas and Electrolyte POCT Diagnostic Testing Companies Worldwide,
2013
Table 8.9: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Blood Gas and Electrolyte POC Market
Table 8:10: Hospital Locations of Point of Care Coagulation Testing
Table 8.11: Selected POC Rapid Coagulation Analyzers, 2013
Table 8.12: Actalyke XL
Table 8.13: Actalyke Mini
Table 8.14: Market Share for Coagulation POCT Diagnostic Testing Companies Worldwide, 2013
Table 8:15: Drivers for Point of Care Coagulation Testing
Table 8:16: Barriers for Point of Care Coagulation Testing
Table 8.17: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Coagulation POC Market
Table 8.18: Selected POC Cardiac Biomarkers, 2014
Table 8.19: Market Share of Cardiac Marker POCT Diagnostic Testing Companies Worldwide, 2013
Table 8.20: POC Cardiac Marker Testing Market: Market Drivers Ranked in Order of Impact
Table 8.21: POC Cardiac Marker Testing Market: Market Restraints Ranked in Order of Impact
Table 8.22: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Cardiac Marker POC Market
Table 8.23: Drug Testing Needs Tier I for Rapid Serum POCT in the Emergency Department
Table 8.24: Stat Urine Testing Drug Recommendations
Table 8.25: Selected POC Substance/Drug Abuse Testing Devices, 2014
Table 8.26: Selected POC Pregnancy Testing Devices, 2012
Table 8.27: Selected POC Fecal Occult Testing Devices, 2013
Table 8.28: ColoCARE Fecal Occult Blood Test
Table 8.29: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Fecal Occult Blood POC Market
Table 8.30: Selected POC Infectious Disease Testing Devices, 2013
Table 8.31: Selected POC Urine Strip Testing, 2013
Table 8.32: Selected POC Cholesterol Testing Devices, 2013
Table 8.33: Competitive Factors Related to HIV Tests
Table 8.34: Global POCT Share of HIV Testing Market, 2013
Table 8.35: Influenza Diagnostic Rapid Tests
Table 8.36: Type of Hepatitis Test: Lateral Flow
Table 8.37: Type of Hepatitis Test: Flow-Through
Table 8.38: Type of Hepatitis Test: Agglutination
Table 8.39: Type of Hepatitis Test: Immunoblot
Table 8.40: AmniSure
Table 9.1: Access Points
Table 9.2: Desktop Adapters—Four Computers
Table 9.3: Desktop Adapters—One Computer
Table 9.4: PCMCIA Adapters
Table 9.5: POCT1-Compliant Connectivity POC Instruments
Table 9.6: POCT Clinical Outcomes in Diabetic Ketoacidosis
Table 9.7: POCT Clinical Outcomes in Arterial Blood-Gas Measurements
Table 9.8: POCT in Three Hospitals—Cost Analysis with Labor Included
Table 9.9: POCT versus Central Lab—Cost Analysis for Glucose Testing
Table 9.10: CLIA Laboratories by Type of Facility
Table 9.11: Financial Comparison for Moderate and Waived CLIA Labs
Table 9.12: Top Ten CMS Survey Deficiencies for CLIA Laboratories
Table 10.1: Key Changes in IVD Business Structure
Table 11.1: Common Genotype Techniques
Table 12.1: Applications for Wireless LAN Technology
Table 12.2: Customized Reports Must Support CAP and JCAHO Requirements
Table 12.3: RALS-Plus POC Market Share
Table 12.4: Applications of RALS Connectivity with POCT Devices
Table 13.1: Abaxis Blood Analysis Diagnostic Tests
Table 13.2: Reagent Discs Offered with the Piccolo Chemistry Analyzers
Table 13.3: Products Marketed by Abbott in the Diagnostic Market
Table 13.4: Alere, Inc.—Net Sales by Geographic Region, 2009-2013
Table 13.5: Bayer AG Financial Figures—Net Sales by Business Sector, 2009-2013
Table 13.6: Bayer AG Financial Figures—Net Sales by Geographic Region, 2009-2013
Table 13.7: BioRad Laboratories, Inc.—Sales by Business Sector, 2008-2013
Table 13.8: BioRad Laboratories, Inc.—Sales by Geography, 2010-2012
Table 13.9: Johnson & Johnson Financial Figures—Net Sales by Major Medical and Diagnostics Businesses,
2010-2013
Table 13.10: Quidel Product Distribution and Sales, 2012 and 2013
Table 13.11: Danaher Corporation Financial Figures—Net Sales by Business Sector, 2009-2013
Table 13.12: Danaher Corporation Financial Figures—Net Sales by Geographic Region, 2010-2013
Table 13.13: Roche Group Financial Figures—Net Sales by Business Sector, 2008-2013
Table 13.14: Roche Group Diagnostics Division—Net Sales by Geographic Region, 2012 and 2013
Table 13.15: Roche Group Financial Figures—Net Sales by Diagnostics Sub-Division, 2008-2013
Table 14.1: Improvements in Achieving ED Operational Efficiency Using POCT
Table 14.2: Test Menu and TAT for ED
Table 14.3: Top Reasons Why POC Cardiac Marker Testing is Implemented in the ED
Table 14.4: Key Areas and Metrics that Hospitals Measure to Assess Efficiency of ED
Table 14.5: Estimates of Patient Costs by DRG

Note: Product cover images may vary from those shown
Point of Care Diagnostic Testing World Market to Jump to $15.9 Billion by 2018

- Abaxis, Inc.
- Abbott Laboratories
- AccuBioTech Co., Ltd.
- Accumetrics, Inc. (Accriva Diagnostics)
- AccuTech, LLC
- ACON Laboratories, Inc.
- Acrongenomics
- AgaMatrix
- Aerscher Diagnostics, LLC
- Akers Biosciences, Inc.
- Alere
- Alfa Scientific Designs, Inc.
- American Bio Medica Corporation
- Any Biotech Oyo Ltd.
- Ark Therapeutics Group Plc
- Arkray, Inc.
- Atlas Genetics Ltd.
- Atonomics A/S
- Audit Diagnostics
- Augurix Diagnostics Ltd.
- Axis-Shield Plc (Alere)
- Axxin
- Bayer Corp.
- Beckman Coulter (Danaher Corporation)
- BioLytical Laboratories
- Biomerica, Inc.
- bioMérieux
- BiOracle
- Bio-Rad Laboratories, Inc.
- BioScan Screening Systems, Inc.
- BioSite
- Calmark Sweden AB
- Calypte Biomedical Corporation
- Chembio Diagnostic, Inc.
- Chempaq A/S
- Cholestech
- Claros Diagnostics (OPKO Healthcare)
- CompuCyte Corporation (Thorlabs)
- Concateno Plc
- Dexcom
- Diagnostics for All
- Enigma Diagnostics Ltd.
- EY Laboratoires, Inc.
- Eurotrol
- Exalenz Bioscience
- GenBio
- Genzyme Diagnostics (Acquired by Sekisui Chemical Co., Ltd)
- Guided Therapeutics, Inc. (SpectRx, Inc.)
- Helena Laboratories
- Hema Diagnostic Systems, LLC
- HemoCue AB
- HemoSense
- Home Diagnostics (Nipro Diagnostics)
- IND Diagnostic
- Instrumentation Laboratory (IL)/Werfen Group
- International Technidyne Corporation (ITC)
- Jant Pharmacal Corporation
- Johnson & Johnson
- Lein Applied Diagnostics
- LifeAssays AB
- LifeSign, LLC
- Medica Corporation
- Medical Automation Systems
- Mediwatch
- Medix Biochemica
- MedMira Laboratories
- MELA Sciences (Formerly Electro-Optical Sciences)
- A. Menarini Diagnostics
- Meretek Diagnostics Group
- Meridian Bioscience
- Micronics
- Minimed, Inc.
- Mitsubishi Chemical Holdings USA, Inc.
- Mitsubishi Kagaku Iatron
- Nanogen (ELITech Group)
- New Horizons Diagnostics
- Nexus/ITC
- Nova Biomedical
- OraSure Technologies, Inc.
- Orion Diagnostica
- Polymedco, Inc.
- Polymer Technology Systems, Inc.
- Prima Biomedical Company
- QBC Diagnostics
- Qualigen
- Quest Diagnostics, Inc.
- Quidel Corporation
- Radiometer Medical
- Response Biomedical Corp.
- Roche Diagnostics
- Savyon Diagnostics
- Seegene
- Sekisui Diagnostics, LLC
- Selfcare, Inc.
- Shanghai Ruicare Medical Co., Ltd.
- Shenzhen Fitconn Technology Co., Ltd.
- Shionogi & Co., Ltd.
- Siemens AG
- Siloam Biosciences, Inc.
- Spectral Diagnostics, Inc.
- StatSure Diagnostic Systems, Inc.
- Step Detect Associates, LLC
- Strategic Diagnostics, Inc.
- Techne Corporation
- Telcare
- Trinity Biotech Plc
- Väsamed, Inc.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos